MedTrace Logo

This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.

NCT01304277 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2021-07-19

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate safety and PK/PD in Canadian Fabry patients.

Conditions

Interventions

BIOLOGICAL

agalsidase alfa

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-17
Primary Completion
2012-12-28
Completion
2012-12-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01304277 on ClinicalTrials.gov